戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  a possible treatment-related grade 5 event (hemoptysis).
2 onary status and prevent further episodes of hemoptysis.
3 cidence, BAA represents a potential cause of hemoptysis.
4 sease (COPD), who presented with non-massive hemoptysis.
5 Twenty-seven percent of patients experienced hemoptysis.
6    He did not report fever, night sweats, or hemoptysis.
7 ns; minor mucocutaneous hemorrhage and major hemoptysis.
8 7 (39%) reported cough, and 5 (28%) reported hemoptysis.
9  of pneumothorax, chest drain placement, and hemoptysis.
10 lied vigorously to all patients with massive hemoptysis.
11  of choice in operable patients with massive hemoptysis.
12 derwent 36 BAE procedures for the control of hemoptysis.
13 on (BAE) is one of the treatment options for hemoptysis.
14 o patient had chest discomfort, coughing, or hemoptysis.
15  along with intermittent episodes of streaky hemoptysis.
16 pneumothorax (13.2%), hemothorax (0.8%), and hemoptysis (0.6%).
17 h as cough (40%), shortness of breath (34%), hemoptysis (10%), or metastases with corresponding local
18 yzed a total of 55 consecutive patients with hemoptysis (14 mild, 31 moderate, and 10 massive) treate
19  hospitalization (7.9% vs. 1.1%, P=0.03) and hemoptysis (6.1% vs. 0%, P=0.01).
20 equent exacerbations of COPD, pneumonia, and hemoptysis after implantation.
21      Eighty-six percent of the patients with hemoptysis and all of those with desensitization and pne
22                          After an episode of hemoptysis and some unusual pain in the patient's right
23 psis-related death, 1 patient died of sudden hemoptysis, and 2 patients developed recurrent IE.
24 ing one case of hematoma and 4 cases of mild hemoptysis, and 30-day mortality (2%-3%) did not differ
25 tcomes were pulmonary hemorrhage, documented hemoptysis, and bleeding complications necessitating int
26 rosis, pulmonary edema, alveolar hemorrhage, hemoptysis, and death, hallmark clinical features of fat
27  or who became critically ill as a result of hemoptysis, and identify predictors of mortality.
28 thm (clinical signs of deep-vein thrombosis, hemoptysis, and pulmonary embolism as the most likely di
29 g toxicities observed included hypertension, hemoptysis, and stomatitis and were seen primarily at th
30 a nonproductive cough and a 1-day history of hemoptysis (approximately 20 mL).
31                 Digital clubbing, fever, and hemoptysis are not typical, and the latter two indicate
32                               There were 326 hemoptysis-associated ICU admissions in 300 patients.
33                                  We describe hemoptysis-associated ICU admissions, including those wh
34   We observed high inhospital mortality from hemoptysis-associated ICU admissions.
35  small postbiopsy hematomas and one of minor hemoptysis, but none required hospital admission.
36 North Carolina Hospitals in the treatment of hemoptysis by BAE.
37 gery is recommended in patients with massive hemoptysis caused by thoracic vascular injury, arteriove
38 o the hospital with productive cough, fever, hemoptysis, chest pain and dyspnea.
39 teral pulmonary crackles without chest pain, hemoptysis, clubbing, or signs of cardiac failure.
40 teral pulmonary crackles without chest pain, hemoptysis, clubbing, or signs of cardiac failure.
41 hemorrhage (coefficient, -0.03; P = .63), or hemoptysis (coefficient, -0.10; P = .60).
42                                        Major hemoptysis, defined as bleeding greater than 240 ml/24 h
43 Organ Dysfunction-2 score within 24 hours of hemoptysis described illness severity.
44 here were two deaths associated with massive hemoptysis despite BAE.
45  include nonproductive cough usually without hemoptysis, dyspnea, hypoxemia, a decrease in hematocrit
46 ciated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarth
47 s hospitalized (HR 2.8; CI 1.3-5.9), massive hemoptysis (HR 2.1; CI 1.1-3.9), and relative drop in FE
48 s were evaluated for pain, pneumothorax, and hemoptysis immediately following and at 1 day, 1 week, a
49 pnea in 92%, fever in 67%, cough in 56%, and hemoptysis in 15%.
50 sional hemorrhage in 353 of 827 (42.7%), and hemoptysis in 20 of 827 (2.4%) patients.
51 dure-related event through 6 months was mild hemoptysis in 47% (14 of 30) patients.
52 ll patients, shortness of breath in 94%, and hemoptysis in 55%.
53  and effective means of treating significant hemoptysis in patients with CF.
54 commendations for life-threatening pediatric hemoptysis incorporating underlying disease pathophysiol
55                                      Massive hemoptysis is a potentially lethal condition that deserv
56                                              Hemoptysis is common in patients with cystic fibrosis (C
57         Finding the etiology and site of the hemoptysis is imperative.
58                                              Hemoptysis is uncommon in children, even among the criti
59                                Demographics, hemoptysis location, and management were collected.
60                    Although the diagnosis of hemoptysis may be established by chest radiograph, many
61 r, including concurrent influenza infection, hemoptysis, multilobar infiltrates, and prehospital anti
62 plications included pulmonary edema (n = 1), hemoptysis (n = 1) and contralateral stent compression (
63  = 3), bronchial stenosis (n = 2), and fatal hemoptysis (n = 2).
64 of CF with respiratory failure (RF, n = 65), hemoptysis (n = 33), antibiotic desensitization (n = 30)
65 rences of pneumothorax, shortness of breath, hemoptysis, nephrectomy, and death.
66 a, no prior venous thromboembolism event, no hemoptysis, no unilateral leg swelling, and no estrogen
67                                              Hemoptysis occurred in 19 of 184 (10.3%) patients who we
68  Mortality was independently associated with hemoptysis onset location, underlying diagnosis, and sev
69 , including those who were critically ill at hemoptysis onset or who became critically ill as a resul
70 ronchiectasis, renal dysfunction, inhospital hemoptysis onset, and higher Pediatric Logistic Organ Dy
71 mbosis, cardiac disease, stroke, hemorrhage, hemoptysis, or GI perforation.
72 rs, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance
73 ay present with wheeze, chest pain, dyspnea, hemoptysis, or symptoms attributable to metastatic disea
74 " opacity and absence of further episodes of hemoptysis over a period of two years.
75 l artery embolization for malignancy-induced hemoptysis prophylaxis.
76 hs; interquartile range, 9.7 - 38.2 months), hemoptysis recurred in 5 (9.3%) patients.
77 nths; interquartile range, 9.7-38.2 months), hemoptysis recurred in 5 (9.3%) patients.
78 late is safe and efficacious for controlling hemoptysis, resulting in low recurrence rates.
79 ory diseases, such as COPD, in patients with hemoptysis, TAE of the BAA and of the pathological bronc
80 erall efficacy of BAE for initial control of hemoptysis was 75% (n = 22) after one session, 89% (n =
81 ition and pneumothorax, drain placement, and hemoptysis was assessed by using multivariable logistic
82                                        Major hemoptysis was associated with squamous cell histology,
83 e occurred in 483 of the 1175 TTLBs (41.1%); hemoptysis was documented in 21 of the 1175 TTLBs (1.8%)
84                                              Hemoptysis was rare under age 20, and its presence over
85 or non-household individuals with cough, and hemoptysis were modestly associated with closer resident
86 tube placement, perilesional hemorrhage, and hemoptysis were recorded.
87 hold exposure to individuals with cough, and hemoptysis, were modestly associated with closer proximi
88     She had no fevers, chills, night sweats, hemoptysis, wheezing, chest pain, palpitations, orthopne
89 on could cause fever, cough, chest pain, and hemoptysis with signs consistent with severe pneumonia 1